DxS to Expand Manufacturing Facility to Meet Demand for K-RAS Companion Dx | GenomeWeb
NEW YORK (GenomeWeb News) – DxS said today that it plans to double the size of its Manchester, UK, manufacturing facility and to hire an undisclosed amount of new staff “over the coming months.”
The company said that the increase in capacity is the result of growing demand for its TheraScreen K-RAS assay, which determines patients’ K-RAS mutation status.
DxS said that the assay is the “preferred method” for K-RAS mutation screening for Amgen's Vectibix colorectal cancer therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.